Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant need to de

Trial Details

NCT ID

NCT06954480

Phase

PHASE2

Sponsor

Queen Mary University of London

Status

RECRUITING

Cancer Type

HER2 Negative Breast Cancer

Interventions

• Datopotamab Deruxtecan (Dato-DXd)
• Durvalumab

Locations (sample)

• London, United Kingdom|51.50853,-0.12574
• London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

• Willing and able to provide written informed consent.
• Ability to comply with the protocol.
• Female ≥ 18 years of age.
• Triple-negative disease, defined as tumour cells being:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →